The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine
about
Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acidsFocus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase InhibitorsThe renaissance of fixed dose combinations: CombivirA new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidineIn vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analoguesSelection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidineK65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenineIdentification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidineResistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptaseInfluence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosidesInhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogsMutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugsResistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integraseAnti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitroCharacterization of human immunodeficiency virus type 1 resistant to modified cyclodextrin sulphate (mCDS71) in vitroCombination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosineThe nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitorsNovel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidineHuman immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 yearsMetabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitroN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceSelection of resistance-conferring mutations in HIV-1 by the nucleoside reverse transcriptase inhibitors (+/-)dOTC and (+/-)dOTFC.Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions.Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.HIV-1 Transmission, Replication Fitness and Disease Progression.Construction and characterization of a temperature-sensitive human immunodeficiency virus type 1 reverse transcriptase mutantA novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidineIncreased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitroDevelopment of an in vivo assay to identify structural determinants in murine leukemia virus reverse transcriptase important for fidelityWild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidineEfficacy of antiretroviral agents against murine replication-competent retrovirus infection in human cells.The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.Incidence and impact of resistance against approved antiretroviral drugs.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics.The HBV drug entecavir - effects on HIV-1 replication and resistance
P2860
Q24682078-8C6EDA7B-5E68-4F63-AC17-D1BE8D3E650DQ26764925-004B4ACB-9157-4111-B9C5-1FFAF7586F0AQ28279752-23DC3528-4324-4B04-9D84-9A777A8D2883Q28343476-264F37F6-603C-493E-93FD-BBAE91288183Q28343615-7A796DEE-6405-4512-81AE-82E6A4629E9EQ28344137-A2DDE8C9-C9B0-4A6A-B995-4342170A6FB7Q28367386-DCB38A2D-6D25-4264-B370-3CA03C3BDF1BQ28367543-FDD1D1EE-6CCE-49F6-BE1D-2782E1E3A19CQ28367547-91B3E283-39D4-4265-88B8-1D929D759A56Q28367580-15983068-AD86-4F6D-AFED-55C58F342226Q28367642-83F4AD5F-282C-49F5-9184-11A744AA2EB3Q28367663-BC63F7B9-65F4-43E3-AA19-31B5D6F48FE2Q28368842-9553F1F7-5296-4DFA-B14A-7060B872D166Q28369464-0AAE1113-E0E1-43B3-8644-2C5B67017D18Q28371764-FD16C3BD-DDD6-4A8B-B65E-F3B105A71BD1Q28378896-75103F91-7FAA-4437-AB54-DB894D78532AQ28378965-2506861E-82DC-4178-9977-AABE1F6670EFQ28379139-EF30C959-54FC-4775-A767-E2D4C90B9E47Q28379249-58C9CA7B-B3F1-4AAA-905B-0021D8CE9CD1Q28379497-4108BC49-1ED8-439A-A757-9D114EC03DADQ28379499-29073EB5-03A4-47FF-A6E0-A81D9BDD6968Q28379519-58236293-375E-4C61-B1BD-BA5B63E44AC2Q28379621-7F6266DD-FB31-4AAF-B227-939388771790Q28471689-F9075FB2-B613-448D-BE07-50A23E11F8C0Q32066792-249CEB07-5412-4AC4-9DB3-4924CE3347F1Q33748925-4EE2888C-4F75-45FD-9810-70CF1BAA71A1Q33749434-62DF84BB-63A7-48E5-83CF-53B3C7C87D35Q33758570-8DD858CA-EF0B-483A-A7ED-81B0A7F9B74FQ33782366-5F52407F-BA33-47D3-952C-EF7BC6BE6DCCQ33782477-50B2E5AD-889C-4A39-9794-1FCB9905CCC8Q33782815-1695D7E0-4E31-485A-B5B9-2D407AFFF0EAQ33794922-37A329D7-039E-4F34-BCCF-B5DCE7F12E79Q33808236-42E6BDB6-6598-437D-9A00-4ED7EB76CB33Q33821343-6C0DF513-5F65-4654-89D7-3340FB60B04CQ33889635-70DBF0E9-0985-4D54-883A-037EA27C788EQ33966248-94CD10D6-5BA5-48E6-926E-D53DAFFF5273Q33979107-6ED85C01-51BC-4D3D-B71B-698E57DCEDF9Q34529310-35FD157A-3360-4326-8D67-8864937DF182Q34588592-C523141A-DB39-44A2-99DA-AE3871721DF4Q34639926-57CBCA41-1970-4285-9411-525669E9BE72
P2860
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine
description
1993 nî lūn-bûn
@nan
1993 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
The same mutation that encodes ...... 2',3'-dideoxy-3'-thiacytidine
@ast
The same mutation that encodes ...... 2',3'-dideoxy-3'-thiacytidine
@en
The same mutation that encodes ...... 2',3'-dideoxy-3'-thiacytidine
@nl
type
label
The same mutation that encodes ...... 2',3'-dideoxy-3'-thiacytidine
@ast
The same mutation that encodes ...... 2',3'-dideoxy-3'-thiacytidine
@en
The same mutation that encodes ...... 2',3'-dideoxy-3'-thiacytidine
@nl
prefLabel
The same mutation that encodes ...... 2',3'-dideoxy-3'-thiacytidine
@ast
The same mutation that encodes ...... 2',3'-dideoxy-3'-thiacytidine
@en
The same mutation that encodes ...... 2',3'-dideoxy-3'-thiacytidine
@nl
P2093
P2860
P356
P1476
The same mutation that encodes ...... 2',3'-dideoxy-3'-thiacytidine
@en
P2093
M A Parniak
M A Wainberg
P2860
P304
P356
10.1128/AAC.37.6.1390
P407
P577
1993-06-01T00:00:00Z